Yun Zhong
Stock Analyst at Wedbush
(0.52)
# 3,869
Out of 4,829 analysts
30
Total ratings
26.92%
Success rate
-16.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $181 → $212 | $151.46 | +39.97% | 1 | May 2, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $13.65 | +9.89% | 1 | Apr 1, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $42.95 | +62.98% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $3.17 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.33 | +1,115.07% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $38.39 | +90.18% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $3.70 | +224.32% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.25 | +239.39% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $2.13 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $5.99 | +167.34% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $36.27 | +341.14% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $6.99 | +400.72% | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 | $3.50 | +19,900.00% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $12.79 | +259.66% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.41 | +314.94% | 1 | May 5, 2021 |
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $181 → $212
Current: $151.46
Upside: +39.97%
Keros Therapeutics
Apr 1, 2025
Reiterates: Neutral
Price Target: $15
Current: $13.65
Upside: +9.89%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $42.95
Upside: +62.98%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $3.17
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.33
Upside: +1,115.07%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $38.39
Upside: +90.18%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $3.70
Upside: +224.32%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.25
Upside: +239.39%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.13
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $5.99
Upside: +167.34%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $36.27
Upside: +341.14%
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $6.99
Upside: +400.72%
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $3.50
Upside: +19,900.00%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $12.79
Upside: +259.66%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.41
Upside: +314.94%